Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2016 | Preventing cytomegalovirus (CMV) infections in patients receiving bone marrow transplants

Genovefa Papanicolaou • 2 Dec 2016
ASH 2016
Letermovir

Genovefa Papanicolaou, MD, from the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses new therapies for the treatment or prevention of viral infections in patients receiving bone marrow transplants at the American Society of Hematology (ASH) Congress 2016 in San Diego, CA. Over the last 10 to 15 years, Dr Papanicolaou has been involved in trials trying to prevent cytomegalovirus (CMV), which is a major problem in patients receiving bone marrow transplants. She discusses the exciting results of a CMV-prevention trial with letermovir, which has met its primary endpoint (NCT02137772). For patients who receive allogeneic stem cell transplants, this is great news, as CMV infection has large impacts on both their quality of life and morbidity

More from Genovefa Papanicolaou

2:41
CMV treatment for stem cell transplant recipients: antivirals
Genovefa Papanicolaou • 18 Mar 2018
1:06
Vaccines for the treatment of CMV in stem cell transplant recipients
Genovefa Papanicolaou • 18 Mar 2018
The content of VJHemOnc is intended for healthcare professionals